Dyne Therapeutics (NASDAQ:DYN) Trading Up 3.9%

Dyne Therapeutics, Inc. (NASDAQ:DYN) was up 3.9% during mid-day trading on Thursday . The company traded as high as $35.30 and last traded at $35.25. Approximately 132,541 shares changed hands during trading, a decline of 92% from the average daily volume of 1,718,124 shares. The stock had previously closed at $33.92.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DYN shares. Jefferies Financial Group raised their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. HC Wainwright raised their price target on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, May 20th. Oppenheimer reissued an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a report on Monday, May 6th. Finally, Morgan Stanley assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.78.

Dyne Therapeutics Trading Up 2.3 %

The firm’s fifty day moving average is $29.56 and its 200-day moving average is $24.26.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.81). On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,705 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the sale, the insider now directly owns 149,647 shares in the company, valued at approximately $4,230,520.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Oxana Beskrovnaya sold 2,705 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the sale, the insider now directly owns 149,647 shares in the company, valued at approximately $4,230,520.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Richard William Scalzo sold 2,588 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $73,162.76. Following the completion of the transaction, the senior vice president now owns 116,695 shares in the company, valued at approximately $3,298,967.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 202,133 shares of company stock valued at $6,500,387. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 1st quarter valued at $28,000. Ameritas Investment Partners Inc. lifted its position in shares of Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after acquiring an additional 5,541 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter valued at $214,000. Finally, SG Americas Securities LLC acquired a new position in shares of Dyne Therapeutics during the 4th quarter valued at $172,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.